Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4457-4463

  Lv, Shasha ^a   Teugels, Erik ^a   Sadones, Jan ^a   Quartier, Erik ^b   Huylebrouck, Mike ^a   Du Four, Stephanie ^a   Le Mercier, Marie ^c   De Witte, Olivier ^c   Salmon, Isabelle ^c   Michotte, Alex ^a   De Grève, Jacques ^a   Neyns, Bart ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Bevacizumab; Cetuximab; Glioma; IDH1 mutation; Sunitinib

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA EXTRACTION; FEMALE; GENE MUTATION; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR GENE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INDOLES; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECURRENCE;

EID: 84855170315     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM and Prados MD: Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10: 162-170, 2008.
2. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
3. Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J, Delattre JY and Sanson M: Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107: 1891-1897, 2006. (Pubitemid 44582960)
4. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN and Aldape KD: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12: 116-121, 2010.
5. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B and Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE and Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
7. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602, 2008.
8. Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174: 1149-1153, 2009.
9. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN and van den Bent MJ: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73: 1792-1795, 2009.
10. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K and Delattre JY: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154, 2009.
11. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G and von Deimling A: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474, 2009.
12. Horbinski C, Kofler J, Kelly LM, Murdoch GH and Nikiforova MN: Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 68: 1319-1325, 2009.
13. Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, Hartmann C and von Deimling A: PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20: 298-300, 2009.
14. Holmila R and Husgafvel-Pursiainen K: Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing. Cancer Detect Prev 30: 1-6, 2006. (Pubitemid 43374496)
15. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007. (Pubitemid 47103521)
16. van der Hout AH, van den Ouweland AM, van der Luijt RB, Gille HJ, Bodmer D, Bruggenwirth H, Mulder IM, van der Vlies P, Elfferich P, Huisman MT, ten Berge AM, Kromosoeto J, Jansen RP, van Zon PH, Vriesman T, Arts N, Lange MB, Oosterwijk JC, Meijers-Heijboer H, Ausems MG, Hoogerbrugge N, Verhoef S, Halley DJ, Vos YJ, Hogervorst F, Ligtenberg M and Hofstra RM: A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 27: 654-666, 2006.
17. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, Michotte A and De Greve J: Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20: 1596-1603, 2009.
18. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J, Tynninen O, Nupponen N, Michotte A and De Greve J: Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 2010.
19. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T and Sanson M: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16: 1597-1604, 2010.
20. Mason WP and Cairncross JG: Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology 71: 365-373, 2008.
21. Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007, 2009.
22. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM and Hayes DN: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110, 2010.
23. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL and Xiong Y: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324: 261-265, 2009.
24. Thompson CB: Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 360: 813-815, 2009.
25. Lu Y, Liang K, Li X and Fan Z: Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to down-regulation of hypoxia-inducible factor-1 alpha. Mol Cancer 6: 63-64, 2007.